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Summary Inflammation may promote malignant invasion by enhancing cancer cell-associated proteolysis.
Here we present the effect of inflammatory cytokines on the plasminogen activation system of eight human
colon carcinoma cell lines. Tumour necrosis factor a (TNF-a) and interleukin-l,B (IL-1,B) increased in several,
but not all, cell lines the production of urokinase-type plasminogen activator (uPA), tissue-type PA (tPA) and
plasminogen activator inhibitor type 1 (PAI-1) as analysed by zymography, enzyme immunoassays and
Northern analysis. Interleukin 6 (IL-6) had no effect. uPA receptor (uPAR) mRNA levels were also up-
regulated. However, each individual cell line responded differently following exposure to TNF-a or IL-l,i. For
example, there was a dose-dependent up-regulation of uPA and PAI-1 in SW 620 cells, whereas increased uPA
production in SW 1116 cells was not accompanied by an increase in PAI- 1. The TNF-a stimulatory effect was
blocked by anti-TNF-a Fab fragments. All cell lines expressed both types of TNF receptor mRNAs, whereas
no transcript for TNF-a, IL-1If, IL-6, IL-6 receptor or the IL-1 receptors was found. Our results demonstrate
that TNF-a and IL-l, stimulate the plasminogen activation system in tumour cells but the responses differed
even in cells derived from the same tissue origin.
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Tumour-associated macrophages recruited by the inflamma-
tory reaction associated with cancer diseases have been
suggested to favour or, alternatively, to interfere with the
invasive growth of cancer cells (Mantovani et al., 1992;
Dingemans et al., 1993; Levine and Saltzman, 1990; Van der
Boschet et al., 1992; Orosz et al., 1993; Quin et al., 1993).
These conflicting observations are possibly related to the
pleiotropic biological effects mediated by cytokines produced
by the host in response to tumour invasion and metastasis.
TNF-a, IL-l# and IL-6 are typical multifunctional cytokines
secreted mainly by monocyte-macrophages of the solid
tumour mononuclear infiltrate. Tumour cell membrane
vesicles were found to induce the release of macrophage
TNF-oa (Hasday et al., 1990). This may explain that high
plasma concentrations of inflammatory cytokines and blood
mononuclear cell cytokine mRNA levels, in particular of
TNF-a, were found in gastrointestinal cancer patients
(Balkwill et al., 1987; Nakazaki, 1991). Moreover, in situ
hybridisation studies of samples obtained from colon cancer
patients have identified TNF-a-producing cells as belonging
to the macrophage lineage, whereas IL-13 and IL-6 were less
frequently detected (Beissert et al., 1989; Naylor et al., 1990).
This pattern of TNF-a expression is also observed in breast
cancer (Miles et al., 1994). In contrast, in ovarian cancer,
TNF-a mRNA is found in epithelial tumour cells and in
infiltrating macrophages (Naylor et al., 1993). Local
destructive growth and dissemination of cancer cells is
dependent on effective proteolysis of surrounding extracel-
lular matrices. There is much evidence suggesting that PAs
and their respective inhibitors regulate peritumoral tissue
breakdown. In addition, clinical investigations have shown
that the plasminogen activation system may be of importance
in the prognostic assessment of colon cancer (Ganesch et al.,
1994). Cytokines released by the leucocytic infiltrate of
tumoral inflammation may regulate the expression of genes
Correspondence: C Tran-Thang, Institut Suisse de Recherche
Experimentale contre le Cancer (ISREC), Unite de Pathologie
Experimentale, Chemin des Boveresses 155, CH-1066 Epalinges,
Suisse
Received 17 November 1995; revised 27 March 1996; accepted 29
March 1996
governing the proteolytic activity of cancer cells, thus
facilitating or inhibiting the spread of malignancy (Masure
and Opdenakker, 1989; Opdenakker and Damne, 1992).
In this study, we investigated the effects of TNF-a, IL-Ip
and IL-6 on the plasminogen activation system in neoplastic
cells, all derived from the colorectal tissue. We found that
TNF-a and, less markedly, IL-1If, increased the production of
PAs, PAI-1 and uPAR in eight human colon carcinoma cell
lines, whereas IL-6 had no effect. More interestingly, we
observed that the stimulatory effect differed for each cell line.
The pattern of response was not dependent on the cytokine
or cytokine receptor expression of colon cancer cells.
Materials and methods
Cell culture
Eight human colon carcinoma cell types were studied: HT 29,
SW 480, COLO 205, SW 620, SW 1116 were from the
American Type Culture Collection (Rockville, MD, USA),
while COSUT, CO 112 and CO 115 were established in our
laboratory (Cajot et al., 1986; Tran-Thang et al., 1994). HT
29, CO 112 and CO 115 cells were grown to confluency in
Dulbecco's modified Eagle medium (DMEM) supplemented
with 5% heat-inactivated fetal calf serum (FCS), 4 mM L-
glutamine, 100 IU ml-' penicillin and 100 ug ml-1 strepto-
mycin; SW 480, SW 620, SW 1116 were maintained in
Leibovitz's L-15 medium, and COSUT in McCoy's 5A. Both
media were supplemented with 10% FCS, 4 mM L-glutamine
and antibiotics. Cells were trypsinised with 7 ml trypsin-
EDTA and neutralised with 8 ml of FCS-containing culture
media, plated at 2 or 4 x 106 cells per well in 6- or 12-well
plates, and left overnight in FCS-containing media. Cells
were washed three times in serum-free culture medium and
incubated for 24 h in the absence or presence of cytokine
under defined experimental conditions.
Conditioned media were collected for sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE),
zymography and enzyme immunoassays (EIAs). After 24 h,
cells were counted and viability was determined by trypan
blue dye exclusion. Northern analysis was performed on
RNA extracted from cells cultured in 75 cm2 flasks until
confluency. Culture media were replaced overnight before
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exposure to serum-free media lacking or containing
cytokines. Human recombinant TNF-a (specific activity
1.1 x 109 U mg-', Boehringer Ingelheim, Vienna, Austria)
was generously given by Dr F Lejeune (Centre Pluridiscipli-
naire d'Oncologie, CHUV, Lausanne, Switzerland), recombi-
nant human IL-1# (Glaxo, Geneva, Switzerland) and non-
immune murine monoclonal Fab fragments were kindly
provided by Dr R McDonald (Ludwig Institute, Lausanne,
Switzerland), recombinant human IL-6 (Sandoz, Basle,
Switzerland) and anti-TNF-a monoclonal Fab fragments
(Knoll AG, Ludwigshafen, Germany) were a gift of Dr D
Heumann (Division des Maladies Infectieuses, CHUV,
Lausanne, Switzerland). The biological activity of IL-6 used
was tested on 7TD1 hybridoma cells and was
1.3 x 106 U mg- (van Snick et al., 1986). The purity of all
recombinant cytokines was >98% as estimated by SDS-
PAGE. Cytokine and cytokine receptor mRNA expression
profiles were studied in cells cultured with fresh FCS-
containing media for 24 h. All cell lines were free of
mycoplasma. All culture reagents were purchased from
Gibco, Life Technologies Ltd., Paisley, UK.
Zymographic analysis and enzyme immunoassays of PAs and
PAIs
Serum-free conditioned media were collected by centrifuga-
tion at 4400 g for 10 min and stored at - 80°C until thawing
for SDS-PAGE zymographic analysis (Tran-Thang et al.,
1994; Heussen and Dowdle, 1980) and PA, PAI antigen
determinations using EIAs according to the manufacturer's
recommendations (TintElize for uPA, tPA, PAI-I and PAI-2
from Biopool, Umea, Sweden).
Northern blot analysis
PolyA+ RNA extracted from cell lines, electrophoresed under
denaturing conditions using formaldehyde and formamide,
was transfered to nitrocellulose. Blots were hybridised to
human uPA, uPAR, tPA, PAI-1, PAI-2 and mouse P-actin
cDNA fragment probes as previously described (Tran-Thang
et al., 1994). For cytokine and cytokine receptor expression,
the following probes were used: a 1 kb HindIII-EcoRI
fragment from human TNF-cx cDNA, a 300 bp PstI-EcoRI
fragment from human IL-1# cDNA, a 298 bp Xbal-SalI
fragment from human IL-6 cDNA (A Shaw, Glaxo, Geneva),
PCR-generated cDNA fragments of the 55 kDa or 75 kDa
human TNF-a receptor (TNF-R, or TNF-R2) were obtained
as previously described (Tada et al., 1994), a 477 bp
HindIII-EcoRI cDNA fragment from human IL-1 type 1
receptor (IL-i-RI) (Sims et al, 1988), and a 750 bp EcoRI-
Sall cDNA fragment from human IL-1 type 2 receptor (IL-1-
R2) (McMahan, 1991) (kindly provided by Dr J E Sims,
Immunex, Seattle, Washington, USA), a 1.7 kb PstI digest of
human IL-6-R cDNA (Yamasaki et al., 1988) (obtained from
Dr T Kishimoto, Division of Immunology, Yamada-Oka,
Suita, Osaka, Japan).
Results
TNF-cx and IL-/I, modulate the plasminogen activation system
of human colon carcinoma cells
Serum-free conditioned media from eight colon carcinoma
cell lines, incubated for 24 h in the absence or presence of
TNF-cx (20 ng ml-') or IL-I# (5 ng ml-'), were subjected to
SDS-PAGE zymographic analysis. Figure 1 shows the
conditioned media of the analysed colon carcinoma cell
lines stimulated with TNF-a or with IL-1I3. These cell lines
expressed higher PA activity following stimulation when
compared with the conditioned media of untreated cells. The
increased PA activity was tPA-related in CO 115 cells and
tPA/uPA-related in SW 1116 cells and uPA-related in other
cell lines. Zymography of TNF-a-treated SW 620 cell-
conditioned media also revealed faint lytic activity at a
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Figure 1 SDS-PAGE zymography of human colon carcinoma
cell conditioned media treated with TNF-a or IL-,IB. Standards of
high and low molecular weight uPA and tPA activity (lanes uPA
and tPA). Serum-free conditioned media of colon carcinoma cells
were collected after 24h incubation in the absence (control) or in
the presence of TNF-ax (20 ng ml- 1) (+ TNF) or IL-1I, (Sngml- 1)
(+ IL-1). The number in brackets under each lane indicates the
cell count x 106 of corresponding conditioned medium analysed
by zymography.
higher molecular weight of approximately 90 kDa, which
might correspond to uPA-PAI-l complex activity. With the
exception of TNF-oa-treated CO 115 cells, 24 h cytokine
exposure did not influence the growth rate of tumour cells, as
determined by comparing the cell counts in the absence or
presence of cytokine (number in brackets under each lane).
A quantitative determination of antigen concentrations of
uPA, tPA, PAI-I and PAI-2 using EIAs in conditioned media
of the colon carcinoma cells treated or not with TNF-a or
IL-i,B confirmed the findings made by zymographic analysis
(Table I). There was some interexperimental variation in the
constitutive PA and PAI-I expression by colon carcinoma
cells under identical culture conditions. The results of
experiments performed in duplicate, however, gave less than
10% variability. The pattern of responses induced by TNF-ac
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Table I Effect of inflammatory cytokines on the plasminogen
activation system of human colon carcinoma cells
PA and PAI Human colon carcinoma cells with
antigen TNF-o IL-1,8
ng mrl 10-6 cells None 20 ng ml- 5 ng mrl
HT 29
uPA < 0.1 <
tPA < < <
PAI-I 0.6 11.3 3.7
SW 480
uPA < 0.2 0.1
tPA < 0.4 <
PAI-I 2.0 17.2 45.1
COSUT
uPA 0.1 0.1 0.5
tPA < < <
PAI-I 1.1 1.9 4.5
COLO 205
uPA < 1.2 4.1
tPA < < <
PAI-I < < <
CO 112
uPA < 0.5 0.3
tPA < <
PAI-I < < <
CO 115
uPA < < <
tPA 0.3 20.8 2.2
PAI-i < < <
SW 620
uPA 0.08 1.6 0.24
tPA < < <
PAI-I < 5.8 0.9
SW 1116
uPA 1.1 4.3 2.5
tPA 0.3 1.2 1.3
PAI-I 0.5 0.8 1.2
Colon carcinoma cells (2 x 106 per well) were cultured to confluence
in their respective media. After washing with serum-free medium,
cells were incubated without or with TNF-cx (20ngml-') or IL-l,
(5 ng ml-'). The 24 h conditioned media were collected, centrifuged for
10min at 4400g, 4°C and kept frozen at -80°C for PA and PAI EIA.
The corresponding cell counts were determined after cell trypsinisa-
tion. The results, expressed in ng ml- per 106 cells, are the means of
two to three different experiments made in duplicate.
and IL-1I3 were always reproducible although the magnitude
varied as a function of the PA and PAI-I basal production
by colon carcinoma cells in the absence of cytokine. With the
exception of CO 115 cells and SW 480 cells following TNF-a
treatment, PAI-2 was not detectable in these cell lines (data
not shown).
IL-6 (20 ng ml-1) had no effect on PA production nor on
the growth rate of the eight colon carcinoma cell lines when
compared with cells treated under the same culture conditions
but in the absence of cytokine. Exposure of HT 29 and SW
480 cells to various concentrations of IL-6 (2-200 ng ml-')
did not modify their PA production as analysed by SDS-
PAGE analysis and EIAs (data not shown).
The response of the plasminogen activation system induced by
TNF-cx and IL-I# revealed by Northern blot analysis
Figure 2 shows a Northern blot of polyA+ RNA extracted
from colon carcinoma cells cultured in serum-free media for
24 h in the absence (lane 1) or presence of TNF-cx
(20 ng ml-') (lane 2), or IL-,IB (5 ng ml-') (lane 3). The
filter was probed for uPA, uPAR, tPA, PAI-I and PAI-2.
PAI-2 mRNA was not detectable in these cells, with the
exception of CO 115 cells, in which the signal was weak and
not modified by cytokine treatment (data not shown). The
modulatory effect of TNF-a on the plasminogen activation
system of colon carcinoma cells was different for each cell
line. Indeed, TNF-a increased uPA, uPAR, tPA and slightly
PAI-I mRNA levels in SW 480 cells but only uPA in SW
1116 cells, tPA in CO 115 cells, uPAR and PAI-i in HT 29
cells and uPA and uPAR in CO 112 cells. IL-i/ also
regulated the expression of the plasminogen activation system
in a different manner depending on the cell line, for example
in SW 620 cells, it increased uPA and PAI-i mRNA levels,
while affecting only uPA levels in SW 1116 cells. There was
concordance between the results obtained with zymography,
EIAs and Northern analysis.
The modulation of the plasminogen activation system induced
by TNF-a is dose dependent and can be inhibited by anti-TNF-
a Fab fragments
TNF-a increased uPA and PAI-I mRNA levels in SW 620
cells, but only uPA mRNA levels in SW 1116 cells (see
Figure 2). The TNF-a effect was further studied in these two
cell lines. TNF-cx enhanced the production of uPA and PAI-I
antigen in SW 620 cells (Figure 3, upper part). The effect was
dose dependent and was already observed between 0.4 and
2 ng ml -. SW 1116 cells were less sensitive to TNF-a, since
the uPA increase required higher cytokine concentrations (2-
20 ng ml- 1). Furthermore, in SW 1116 cells, PAI- I antigen
levels remained unchanged at TNF-a concentrations up to
40 ng ml-'. Zymographic analysis showed that TNF-a also
stimulated tPA production in SW 1116 cells. The low
molecular weight uPA lysis band was also present at high
TNF-ac concentrations in the case of SW 1116 cells (Figure 3,
lower part).
The TNF-cx-mediated increased production of uPA in SW
1116 cells was inhibited by Fab fragments directed against
TNF-a but not by non-immune Fab fragments. On the other
hand, the PAI-I production remained unchanged by TNF-a
treatment in the presence or absence of anti-TNF-ax or non-
immune Fab fragments (Figure 4). This indicates that the
observed effects were caused by TNF-a and not by
contaminants in the TNF-cx preparation.
The human colon carcinoma cells express the two types of
TNF-a receptors
The variant behaviour of the colon carcinoma cell lines could
have been caused by a different expression of inflammatory
cytokines or cytokine receptors. Therefore, we analysed their
expression by Northern analysis. All cell types expressed, in
varying amounts, the 55 and 75 kDa types of TNF receptors
(TNF-R, and -R2). There was no correlation between the
expression levels of the two types of TNF receptors. For
example, SW 480 and SW 620 expressed similar levels of
TNF-RI, but differed significantly in TNF-R2 expression
levels (Figure 5). In addition, there was no relationship
between the pattern of TNF receptor expression and the
extent of modulation of the plasminogen activation system by
TNF-a. Even after prolonged autoradiography, no signal was
obtained for TNF-cx, IL-I#, IL-6 and receptors for IL-1 and
IL-6.
Discussion
A broad spectrum of acute-phase proteins are synthesised
during inflammation and their expression has been shown to
be modulated by TNF-a, IL-,IB and IL-6 (Perlmutter et al.,
1986; Heinrich et al., 1990). In the present study, we have
shown that exposure of human colon carcinoma cells to the
inflammatory cytokines, TNF-a and IL-,IB, increases the
production of proteins that regulate tumour cell-mediated
plasminogen activation. The augmented generation of uPA,
tPA, PAI-I and uPAR was demonstrated by SDS-PAGE
zymography (Figure 1), antigen determination (Table I) and
RNA analysis (Figure 2). All of the eight cell lines
responded to TNF-cx, whereas only four of the eight were
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Figure 2 Northern analysis of uPA, uPAR, tPA and PAI-i expression in colon carcinoma cells treated with TNF-a or IL-Ifl.
PolyA+ RNA was extracted from colon carcinoma cells cultured in their serum-free medium for 24h in the absence (lane 1) or
presence of TNF-a (20ngml-1) (lane 2) or IL-1I3 (5ngml-1) (lane 3).
responsive to IL-1Ip. There was a discrepancy between PAI-I
antigen levels and mRNA expression following stimulation
with cytokines. For example, in SW 480 cells treated with
TNF-a, a large increase in PAI-I antigen was measured,
whereas only a modest augmentation of RNA transcription
level was observed. This could be related to the short half-
life of PAI-I mRNA. Also, the transient effect of PAI-I
mRNA induction by TNF-a or IL-1# may in part explain
this discrepancy (Loskutoff, 1991; Healy and Gelehrter,
1994). Remarkably, IL-6 had no effect on all eight colon
carcinoma cells lines examined (data not shown). In HepG2
human hepatoma cells, TNF-a and IL-1# have been
reported to increase uPA or PAI-1 levels, whereas IL-6
did not (Healy and Gelehrter, 1994). Little is known about
the effect of IL-6 on the plasminogen activation system in
cancer cells. Our findings suggest that, at least in colon
carcinoma cells, the plasminogen activation system is
unresponsive to IL-6.
TNF-a has been reported to modulate the expression of
the PAs, PAIs and uPAR in various normal and malignant
cells (Schleef et al., 1988; Van Hinsbergh et al., 1990;
Niedbala and Picarella, 1992; Marshall et al., 1992; Medcalf
et al., 1988; Waltz et al., 1993; Sitrin et al., 1994; Georg et al.,
1989; Vassalli, 1992). We studied the effects of TNF-a in
detail and demonstrated a dose-dependent TNF-a-induced
increase in the plasminogen activation system of colon
carcinoma cells (Figure 3). Similar results have been
reported in tumour cell lines originating from different
tissue types (Georg et al., 1989). The concentration range
of TNF-oa used by us and others (Medcalf et al., 1988; Georg
et al., 1989) was similar to those found in sera of cancer
patients (Balkwill et al., 1987). Of particular interest, we
showed that even in cancer cells derived from the same tissue
type, i.e. colon carcinoma cells, the pattern of response to
cytokine stimulation differed greatly depending on the cell
line (Table I and Figure 2). Therefore, hypotheses on the
biological role of inflammatory mediators acting on the
modulation of cancer cell-associated proteolyis should not be
drawn from observations made in one particular cell line or
in a limited number of tumour cell types. On the other hand,
our findings may explain the contradictory observations
which suggest that TNF-a can facilitate or alternatively
inhibit tumour progression (Orosz et al., 1993; Quin et al.,
1993).
We further characterised the cytokine and cytokine
receptor profiles of the eight colon carcinoma cell types
(Figure 5). All cell lines expressed the two types of TNF
receptor transcripts as evidenced by Northern analysis. Our
observation is in agreement with the identification of both
TNF receptors in the majority of cell types and tissues
(Loescher et al., 1990; Schall et al., 1990; Smith et al., 1990).
It is possible, however, that in vivo, low levels of TNF-a
receptor expression preclude their identification as in the case
of breast cancer (Miles et al., 1994). TNF-cx, IL-,IB and IL-6
transcripts were not detectable, nor were those of IL-1 and
IL-6 receptors. To our knowledge, there are only a few
reports dealing with cytokine and cytokine receptor
expression in colon carcinoma cell lines (Gaffney et al.,
1988; Jung et al., 1995). Expression of a large variety of
cytokine and cytokine receptor genes was reported in
melanoma and sarcoma tumours but using the polymerase
chain reaction (Colombo et al., 1992; Pekarek et al., 1993;
Mattei et al., 1994). In colon cancer patient tissue samples,
TNF-a RNA expression was localised, by in situ hybridisa-
tion, in tumour-infiltrating stromal macrophages (Beissert et
al., 1989; Naylor et al., 1990). No TNF-a transcript was
detected in the eight human colon carcinoma cell lines and
using a cytotoxic/cytostatic assay involving TNF-susceptible
WEHI 164 fibrosarcoma cells, we found no TNF-a-
dependent activity in 10-fold concentrated conditioned
media (data not shown). All these cell lines responded to
TNF-ac by increasing the expression of proteins implicated in
the plasminogen activation.
We observed that colon carcinoma cell lines which
responded to IL-1I,, did not exhibit detectable levels of its
receptors. There are two known receptors for IL-1, the type 1
is believed to mediate the biological responses, whereas the
function of the type 2 receptor is still unclear (Sims et al.,
1989; Deyerle et al., 1992; Sims et al., 1993). Many IL-1-
sensitive cells are known to express very low levels of type 1
IL-1-R (Sims et al., 1993). Despite low level expression or
even undetectable expression of type 1 receptor, these cells
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Figure 3 Dose- response curve of the effect of TNF-a
concentration on PA and PAI-l production in SW 620 and SW
1116 cells. The colon carcinoma cells were plated at 2 x 106 cells
per well and left overnight in FCS-containing media. After
washing with serum-free medium, cells were incubated with
different concentrations of TNF-a. The 24 h conditioned media
were collected for uPA and PAI-I EIA. The results, expressed in
ng ml- per 106 cells, are the means of two experiments
performed in duplicate. The inserts illustrate the SDS-PAGE
zymography of representative conditioned media of cells treated
with corresponding TNF-a concentrations. The first two lanes are
standards of high and low molecular weight uPA and of tPA.
were capable of responding to IL-I4 (Deyerle et al., 1992;
Sims et al., 1993). Therefore, the absence of IL-1-R mRNA
expression in colon carcinoma cells is not contradictory to
the IL-If,-induced enhancement of the plasminogen activa-
tion system in these cells.
Based on our observations, we suggest that the macro-
phage-derived cytokines, TNF-a and IL-1p, can stimulate the
plasminogen activation system of colon carcinoma cells.
However, the pattern of response varied greatly depending on
the cell type and we could not correlate this with the
abundance of one or the other TNF-R type. Moreover, we
have not analysed the TNF-R expression upon TNF-o
treatment. Internalisation of TNF-R (Imamura et al., 1987),
as well as protease-mediated shedding of TNF-R (Ding and
Porteu, 1992), followed by resynthesis of newly formed
receptors by monocytes under TNF-ax stimulation have been
described. How such putative regulation may affect the
plasminogen activation system expression in colorectal
carcinoma cells is not known. The TNF-R55-mediated
signalling pathway has been elucidated but the role of
TNF-R75 is still under debate (Heller and Kronke, 1994).
How the signal mediated by these two receptors modulates
the transcriptional activity of the plasminogen activation
system also remains unclear. It is suggested that TNF-R75
Figure 4 Effect of anti-TNF-a Fab fragments on the increased
production of uPA in SW 1116 cells. Approximately 4 x 106 cells
per well were plated and left overnight in their FCS-containing
media. After washing with serum-free media, cells were incubated
for 24h in the absence (control) or in the presence of TNF-ax
(1Ongml-l (+ TNF-o) alone or together with anti-TNF-a Fab
fragments (1O jug ml-) (+ anti-TNF-a) or non-immune Fab
fragments (+ control Fab). The uPA (R) and PAI-I ([l)
antigens were determined in the 24 h conditioned media by EIAs.
The results are the means+s.d. of two experiments performed in
duplicate.
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Figure 5 Northern analysis of cytokine and cytokine receptor
expression in colon carcinoma cells. The polyA+ RNA extracted
from colon carcinoma cell lines cultured in FCS-containing media
was analysed by Northern blot hybridisation using probes for
TNF-a, IL-,lB, IL-6, TNF-a receptors 1 and 2 (TNF-R1 and -R2),
IL-1 receptors 1 and 2, IL-6 receptor and ,B-actin as described in
the Materials and methods section. Only autoradiograms of the
TNF receptor hybridisation are illustrated. No signal was
obtained with the other probes even after 2-3 weeks of
autoradiography exposure.
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might recruit TNF-x for signalling through TNF-R55
(Tartaglia et al.. 1993) or alternatively. TNF-R75 might act
by its own signalling pathway and by regulating the access of
TNF-x to TNF-R55 (Bigda et al., 1994; Erikson et al., 1994).
In view of our results. we hypothesise that activated
tumour-infiltrating macrophages secreting TNF-x and IL-I:
may modulate positively or negatively the plasminogen
activation associated with cancer cells. thus favouring or
interfering with the degradation of surrounding penrtumoral
tissues. The paracrine activation of cancer cell plasminogen-
dependent proteolysis may be important in determining the
invasive and metastatic phenotype of colon cancer.
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